

The Basics Of Fluid Biomarkers For Alzheimer's Disease And Other Dementia

Friday, July 26, 2024 | 8 a.m. – 5 p.m.

Marriott (Grand Ballroom H) — Philadelphia, USA

All times are in Eastern Standard Time

In-person attendance only

Overview

This workshop aims to provide participants with an in-depth understanding of the fundamental principles, inherent limitations, and clinical and research applications of the most common AD biomarkers present in cerebrospinal fluid (CSF) and blood. The workshop is aligned with ongoing research efforts in other fields and thus also provides an overview of the status of fluid biomarkers for other causes of dementia. This workshop will include fundamental laboratory-focused sessions that capture the basics of neurochemistry, sample pre-analytics, assay methods and development, quality control, and regulatory considerations. It will also incorporate clinical practice-focused sessions that cover considerations for AD fluid biomarker implementation, the context of use, disclosure, and the gaps and opportunities in this field.

These sessions will cover both standard AD biomarkers and emerging biomarkers and novel platforms in development. Lectures will include interactive poll questions within presentations followed by Q&A sessions and discussions to ensure that participants understand the current and future state of fluid biomarkers.

The Basics of Fluid Biomarkers in Alzheimer's Disease is organized by the ISTAART Biofluid Based Biomarker PIA (BBB-PIA) and by the Alzheimer's Association Global Biomarkers Standardization Consortia (GBSC).

Organizing Committee

- Marta del Campo, Barcelonacβeta Brain Research Center
- Charlotte Teunissen, Amsterdam UMC
- Alicia Algeciras-Schimnich, Mayo Clinic
- Thomas Karikari, University of Pittsburgh & University of Gothenburg
- Jeff Dage, Indiana University School of Medicine

Presenters

- Kaj Blennow, Sahlgrenska Academy at the University of Gothenburg
- Michelle Mielke, Wake Forest University School of Medicine
- Olivia Belbin, Memory Unit at Sant Pau Hospital
- Suzanne Schinder, Washington University in St. Louis
- Jonathan Schott, University College London
- Inge Verberk, Amsterdam UMC
- Henrik Zetterberg, Sahlgrenska Academy at the University of Gothenburg

Target Audience

This ISTAART Immersive workshop is targeted to attendees who are in clinical practice, research and teaching roles and is pitched at a beginner-intermediate-advanced level.

Learning Objectives

1. Define the fundamental principles, inherent limitations, and clinical and research applications of the most common biomarkers used in AD and found in CSF and blood.
2. Summarize the fundamentals of CSF physiology, basics of neurochemistry, technical issues of sample collection, storage, analysis methods, quality control, and regulatory issues.
3. Discuss the latest in cutting-edge biomarker technology, including blood-based biomarkers, with the current understanding of how biomarkers track the progression in AD and their use in other dementias.

Registration

Educational workshops are offered for in-person attendance only. Workshops require a separate registration fee in addition to AAIC full conference registration, or they may be purchased as stand-alone events.

Agenda

Time	Session Details	Speakers and Moderator
Session 1: Laboratory - Basics		
7:00 a.m.	Light Breakfast	
8:20 a.m. - 8:40 a.m.	Overview of Core CSF Alzheimer's Disease Biomarkers	Kaj Blennow
8:45 a.m. - 9:05 a.m.	Overview of Core Blood Based Alzheimer's Disease Biomarkers	Henrik Zetterberg
9:10 a.m. - 9:30 a.m.	5 Things to know: CSF and Blood Biomarkers and Analytics/Webinar Overview	Inge Verberk
9:35 a.m. - 9:45 a.m.	Q&A	
9:50 a.m. - 10:10 a.m.	Break	
Session 2: Alzheimer's disease and related dementias biomarker discovery		
10:15 a.m. - 10:35 a.m.	Accelerating Biomarker Development Through Omics Discovery	Olivia Belbin
10:40 a.m. - 11:00 a.m.	Emerging Fluid Biomarkers for Alzheimer's Disease	Thomas Karikari
11:05 a.m. - 11:25 a.m.	Non-AD Biomarkers (FTD, LBD, DS/AD, TBI, VCID)	Charlotte Teunissen
11:30 a.m. - noon	Discussion and Poll Question	
12:05 p.m. - 1:05 p.m.	Lunch	
Session 3: Translational Considerations of CSF and Plasma Biomarkers		

1:05 p.m. - 1:25 p.m.	Using Biofluid Markers for Clinical Trial Enrichment and Pharmacodynamics	Jeff Dage
1:30 p.m. - 1:50 p.m.	Effects of Sociodemographics, Medical Comorbidities, Drugs on Biomarkers	Michelle Mielke
1:55 p.m. - 2:20 p.m.	Practical Considerations for Clinical Implementation of CSF and Blood Based biomarkers	Alicia Algeciras-Schimmich
2:20 p.m. - 2:35 p.m.	Q&A	
2:35 p.m. - 2:55 p.m.	Break	
Session 4: Clinical – Case Based Approaches		
3:00 p.m. - 3:30 p.m.	Appropriate Use Recommendations and Context of Use for CSF Biomarkers for Alzheimer's Disease and Other Dementia (Case-Based Approach)	Jonathan Schott
3:35 p.m. - 4:05 p.m.	Appropriate Use Recommendations and Context of Use for Blood Biomarkers for Alzheimer's Disease (Case-Based Approach)	Suzanne Schindler
4:05 p.m. - 4:30 p.m.	Discussion and Poll Question	
4:30 p.m. - 5:00 p.m.	Workshop Survey	